abstract |
The invention relates to the use, as a vaccine molecule in a mammal, of a PSA, such as leishmania, or a part of this PSA having immunogenic properties, said PSA designated hereinafter by ES PSAr, presenting in soluble, native, recombinant form. It also relates to a vaccine composition for the prevention and / or treatment of leishmaniases comprising an ES PSAr protein. |